Cardiac safety evaluation in cancer clinical trials

Area of Science:

• Cardiology
• Oncology
• Clinical Trials

Background:

• Cancer therapeutics, including anthracyclines and trastuzumab, can cause significant cardiac adverse effects like heart failure and left ventricular dysfunction.
• Accurate identification and quantification of these cardiac events are vital for comparing treatment efficacy and safety in clinical trials.

Purpose of the Study:

• To evaluate methods used in phase III clinical trials over the past decade for identifying and quantifying cardiac dysfunction induced by cancer therapies, using trastuzumab as a model.
• To highlight the challenges in accurately measuring cardiac adverse events due to subjective diagnoses and interobserver variability in measurements like left ventricular ejection fraction.

Main Methods:

• Review of phase III clinical trials conducted over the last 10 years.
• Analysis of methodologies employed for diagnosing heart failure and assessing left ventricular function.
• Assessment of the utilization of quality assurance techniques to minimize measurement variability.

Main Results:

• Significant heterogeneity was observed in the methods used to diagnose cardiac adverse events across clinical trials.
• The application of quality assurance techniques to reduce measurement variability was found to be low.
• Challenges in accurately quantifying subjective clinical diagnoses and objective measurements with high interobserver variability were identified.

Conclusions:

• There is a need to standardize the assessment of cardiac events in cancer clinical trials to ensure accurate comparisons between treatment arms and trials.
• Proposed methods aim to reduce variability in cardiac event assessment, thereby improving the reliability of cardiac safety data.
• Standardization will facilitate more robust comparisons of treatment-induced cardiac toxicity and enhance overall patient safety in oncology.